- Home
- GCTS vs AGEN Comparison
GCTS vs AGEN Comparison
Compare GCTS & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCTS
- AGEN
- Stock Information
- Founded
- GCTS 1998
- AGEN 1994
- Country
- GCTS United States
- AGEN United States
- Employees
- GCTS N/A
- AGEN N/A
- Industry
- GCTS Blank Checks
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GCTS Finance
- AGEN Health Care
- Exchange
- GCTS Nasdaq
- AGEN Nasdaq
- Market Cap
- GCTS 102.6M
- AGEN 96.2M
- IPO Year
- GCTS N/A
- AGEN 2000
- Fundamental
- Price
- GCTS $2.02
- AGEN $3.32
- Analyst Decision
- GCTS Strong Buy
- AGEN Buy
- Analyst Count
- GCTS 1
- AGEN 3
- Target Price
- GCTS $5.00
- AGEN $10.50
- AVG Volume (30 Days)
- GCTS 116.8K
- AGEN 360.9K
- Earning Date
- GCTS 04-03-2025
- AGEN 03-13-2025
- Dividend Yield
- GCTS N/A
- AGEN N/A
- EPS Growth
- GCTS N/A
- AGEN N/A
- EPS
- GCTS N/A
- AGEN N/A
- Revenue
- GCTS $11,532,000.00
- AGEN $160,427,000.00
- Revenue This Year
- GCTS N/A
- AGEN N/A
- Revenue Next Year
- GCTS $463.17
- AGEN $26.02
- P/E Ratio
- GCTS N/A
- AGEN N/A
- Revenue Growth
- GCTS N/A
- AGEN 59.00
- 52 Week Low
- GCTS $1.97
- AGEN $2.50
- 52 Week High
- GCTS $56.00
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- GCTS 40.86
- AGEN 45.96
- Support Level
- GCTS $1.97
- AGEN $3.09
- Resistance Level
- GCTS $2.36
- AGEN $3.68
- Average True Range (ATR)
- GCTS 0.14
- AGEN 0.25
- MACD
- GCTS 0.00
- AGEN -0.03
- Stochastic Oscillator
- GCTS 13.92
- AGEN 23.00
About GCTS GCT Semiconductor Holding Inc. Common Stock
GCT Semiconductor Holding Inc. is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).